Thanks mate, it does seem that MSB has negotiated away the need for an additional trial prior to approval if the assay data can show consistency etc.
I'm just cautious to rule this out as a non-issue because I thought that the need for the additional trial was negotiated away when we responded to the first CRL based on MSB comments only to have the FDA repeat the request in CRL #2.
None the less, I am much more confident this time around.
May the odds be in our favour.
Thanks mate, it does seem that MSB has negotiated away the need...
-
- There are more pages in this discussion • 3,109 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.32 |
Change
-0.025(1.86%) |
Mkt cap ! $1.507B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.35 | $1.31 | $2.699M | 2.040M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34995 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 10374 | 2 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |